Have a feature idea you'd love to see implemented?
Let us know!
IMVT Immunovant Inc
Price (delayed)
$25.95
Market cap
$3.81B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.22
Enterprise value
$3.34B
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous
Highlights
Immunovant's debt has shrunk by 92% YoY and by 32% QoQ
The equity has soared by 78% YoY but it has contracted by 18% from the previous quarter
IMVT's quick ratio is down by 43% since the previous quarter but it is up by 6% year-on-year
IMVT's net income is down by 27% YoY and by 19% from the previous quarter
Immunovant's EPS has decreased by 15% QoQ and by 13% YoY
Key stats
What are the main financial stats of IMVT
Market
Valuations
Earnings
Shares outstanding
146.78M
Market cap
$3.81B
Enterprise value
$3.34B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.46
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$323.01M
EBIT
-$322.73M
EBITDA
-$321.8M
Free cash flow
-$272.3M
Per share
Balance sheet
Liquidity
EPS
-$2.22
EPS diluted
-$2.22
Free cash flow per share
-$1.86
Book value per share
$3.07
Revenue per share
$0
TBVPS
$3.52
Total assets
$515.71M
Total liabilities
$66.65M
Debt
$47,000
Equity
$449.05M
Working capital
$440.72M
Debt to equity
0
Current ratio
7.61
Quick ratio
7.12
Net debt/EBITDA
1.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52%
Return on equity
-56.4%
Return on invested capital
N/A
Return on capital employed
-71.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMVT stock price
How has the Immunovant stock price performed over time
Intraday
-0.5%
1 week
1.13%
1 month
-4.46%
1 year
-41.28%
YTD
-38.4%
QTD
-8.98%
Financial performance
How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$352.46M
Net income
-$323.01M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 31% year-on-year and by 18% since the previous quarter
IMVT's net income is down by 27% YoY and by 19% from the previous quarter
Growth
What is Immunovant's growth rate over time
Valuation
What is Immunovant stock price valuation
P/E
N/A
P/B
8.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 15% QoQ and by 13% YoY
The equity has soared by 78% YoY but it has contracted by 18% from the previous quarter
The stock's price to book (P/B) is 37% more than its 5-year quarterly average of 6.2 and 3.7% more than its last 4 quarters average of 8.2
Efficiency
How efficient is Immunovant business performance
IMVT's return on equity is up by 27% year-on-year but it is down by 8% since the previous quarter
IMVT's return on assets is up by 23% year-on-year but it is down by 8% since the previous quarter
Dividends
What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMVT.
Financial health
How did Immunovant financials performed over time
IMVT's total assets has soared by 77% YoY but it is down by 13% QoQ
IMVT's total liabilities has surged by 66% year-on-year and by 48% since the previous quarter
Immunovant's debt is 100% lower than its equity
Immunovant's debt has shrunk by 92% YoY and by 32% QoQ
The equity has soared by 78% YoY but it has contracted by 18% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.